Manmohini Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 13.62%
(FY 2022)
- Ebitda 13.62%
(FY 2022)
- Net Worth -6.55%
(FY 2022)
- Total Assets -11.20%
(FY 2022)
About Manmohini Pharmaceuticals
The Corporate was formerly known as Nmg Realcon Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bijay Gulgulia and Sushma Gulgulia serve as directors at the Company.
- CIN/LLPIN
U52100WB2013PTC194498
- Company No.
194498
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Murshidabad, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Manmohini Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bijay Gulgulia  | Additional Director | 05-Mar-2022 | Current |
| Sushma Gulgulia | Additional Director | 05-Mar-2022 | Current |
Financial Performance and Corporate Structure Insights of Manmohini Pharmaceuticals.
Manmohini Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 13.62% increase in profit. The company's net worth dipped by a decrease of 6.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Manmohini Pharmaceuticals?
In 2022, Manmohini Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Manmohini Health Care Private LimitedActive 13 years 11 monthsBijay Gulgulia and Sushma Gulgulia are mutual person
Five Point Micro Surgery Centre Private LimitedActive 29 years 4 monthsBijay Gulgulia is a mutual person
- Manmohini Academic InstitutionActive 12 years 9 months
Bijay Gulgulia and Sushma Gulgulia are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Manmohini Pharmaceuticals?
Unlock and access historical data on people associated with Manmohini Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Manmohini Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Manmohini Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
